{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:16:00Z","timestamp":1793859360081,"version":"4.6.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015087","name":"Markey Cancer Center, University of Kentucky","doi-asserted-by":"publisher","award":["P30CA177558"],"award-info":[{"award-number":["P30CA177558"]}],"id":[{"id":"10.13039\/100015087","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA177558"],"award-info":[{"award-number":["P30 CA177558"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011343","name":"The University of Iowa Holden Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.euo.2025.04.006","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T15:50:54Z","timestamp":1745596254000},"page":"1461-1465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Presence of an Artificial Intelligence\u2013powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine\/Docetaxel in Patients with High-grade Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"8","author":[{"given":"Vignesh T.","family":"Packiam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"McElree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saum","family":"Ghodoussipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Nimgaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viswesh","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek B.","family":"Allison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan R.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.D.","family":"Anand Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haochen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damir","family":"Vrabac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed M.","family":"Abuzeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirudh","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.04.006_b0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.006_b0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus Calmette-Guerin for the treatment of patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2025.04.006_b0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/JU.0000000000003977","article-title":"A phase 2 trial of intravesical gemcitabine and docetaxel in the treatment of bacillus Calmette-Guerin\u2013naive nonmuscle-invasive urothelial carcinoma of the bladder","volume":"212","author":"Patel","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.04.006_b0020","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2023.06.011","article-title":"Sequential intravesical gemcitabine and docetaxel is an alternative to bacillus Calmette-Guerin for the treatment of intermediate-risk non-muscle-invasive bladder cancer","volume":"6","author":"Tan","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.04.006_b0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JU.0000000000003438","article-title":"Nonrisk-adapted sequential intravesical gemcitabine and docetaxel for nonmuscle-invasive bladder cancer: the time is now","volume":"210","author":"Steinberg","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.04.006_b0030","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.euf.2023.06.006","article-title":"Background and update for ECOG-ACRIN EA8212: a randomized phase 3 trial of intravesical bacillus Calmette-Guerin (BCG) versus intravesical docetaxel and gemcitabine treatment in BCG-naive high-grade non-muscle-invasive bladder cancer (BRIDGE)","volume":"9","author":"Kates","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.04.006_b0035","first-page":"192","article-title":"Predicting response to intravesical BCG in high-risk NMIBC using an artificial intelligence-powered pathology assay: development and validation in an international 12-center cohort","volume":"213","author":"Lotan","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.04.006_b0040","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.006_b0045","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.eururo.2024.08.001","article-title":"Bladder-sparing therapy for bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer: International Bladder Cancer Group recommendations for optimal sequencing and patient selection","volume":"86","author":"Li","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.006_b0050","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:43:03Z","timestamp":1778143383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2588931125001002"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.006","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Presence of an Artificial Intelligence\u2013powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine\/Docetaxel in Patients with High-grade Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}